- Home
- KAPA
KAPA
KAIROS PHARMA LTD
as 11-21-2024 4:00pm EST
Stocks
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 21.3M | IPO Year: | 2024 |
| Target Price: | $9.00 | AVG Volume (30 days): | 720.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.22 - $4.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest KAIROS PHARMA LTD News
KAPA Breaking Stock News: Dive into KAPA Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Kairos Pharma Approved to Dual List on Upstream
GlobeNewswire
a month ago
Kairos Pharma to Present at the LD Micro Main Event XVII
GlobeNewswire
a month ago
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
GlobeNewswire
2 months ago
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
GlobeNewswire
2 months ago
Kairos Pharma Closing of $6.2 Million Initial Public Offering
GlobeNewswire
2 months ago
Kairos Pharma Prices $6.2 Million Initial Public Offering
Compare KAPA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KAPA KAIROS PHARMA LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.